Automate Your Wheel Strategy on NKTR
With Tiblio's Option Bot, you can configure your own wheel strategy including NKTR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NKTR
- Rev/Share 0.4136
- Book/Share 0.0651
- PB 153.3797
- Debt/Equity 7.3036
- CurrentRatio 3.2414
- ROIC -0.5511
- MktCap 1859178960.0
- FreeCF/Share -0.8448
- PFCF -10.4339
- PE -15.8382
- Debt/Assets 0.3916
- DivYield 0
- ROE -2.6209
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NKTR | Jefferies | Hold | Buy | -- | $2 | April 11, 2025 |
| Upgrade | NKTR | Oppenheimer | Perform | Outperform | -- | $6 | March 14, 2025 |
| Initiation | NKTR | B. Riley Securities | -- | Buy | -- | $4 | Jan. 8, 2025 |
| Initiation | NKTR | H.C. Wainwright | -- | Buy | -- | $6.5 | Dec. 10, 2024 |
| Resumed | NKTR | BTIG Research | -- | Buy | -- | $4 | Sept. 30, 2024 |
News
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Read More
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Nektar Therapeutics (NASDAQ:NKTR ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Corinne Franklin – Investor Relations Howard Robin – President and Chief Executive Officer Jonathan Zalevsky – Chief Research and Development Officer Sandra Gardiner – Chief Financial Officer Conference Call Participants Dominic Risso-Gill – Piper Sandler Julian Harrison – BTIG Jay Olson – Oppenheimer Roger Song – Jefferies Mayank Mamtani – B. Riley Securities Arthur He – H.C.
Read More
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Read More
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Negative
NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected.
Read More
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
Published: February 26, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs).
Read More
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
-- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D). Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways.
Read More
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m.
Read More
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Published: February 10, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs).
Read More
About Nektar Therapeutics (NKTR)
- IPO Date 1994-05-03
- Website https://www.nektar.com
- Industry Biotechnology
- CEO Mr. Howard W. Robin
- Employees 61